Phase 2 N=129 Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Freedom From Any Atrial Arrhythmias — 24; 23 Participants — p=.83
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
N/A N=1,833 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
Atrioventricular Block · Ventricular Dysfunction
Primary: Total Mortality — 307; 305 Participants — p=0.3492
N/A N=23 AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals
Atrioventricular Block · Sick Sinus Syndrome · Symptomatic Bradycardia
Primary: Comparison of Change in Echocardiographic Parameters LV Dimension at End-diastole, LV Dimension at End-systole, and Tricuspid Annular Plane Systolic Excursion (cm) From…
N/A N=101 Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block
Bifascicular Block · Syncope
Primary: Combined Endpoint Defined as First Occurrence Among the Following Events 1)Syncope Episode of Any Origin; 2)Presyncopal Episode With Documented Cardioinhibitory Origin…
N/A N=186 BIOTRONIK Conduction System Pacing With the Solia Lead
Bradycardia · Atrioventricular Block · Left Bundle-Branch Block
Primary: Serious Adverse Device Effect (SADE)-Free Rate at 3 Months — 98 Percentage of participants without SADE — p=<0.0001
N/A N=26 Junctional AV Ablation in CRT-D: JAVA-CRT
Systolic Heart Failure · Atrial Fibrillation (Permanent)
Primary: Number of Patients With Reduction ≥ 15% in Left Ventricular End-systolic Volume (LVESV) — 5; 6 Participants — p=1.00
Phase 4 N=810 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)
Tachycardia, Atrioventricular Nodal Reentry
Primary: Device or Procedure Related AV Block Persistent Through Discharge From Hospital. — 0; 0 participants
N/A N=242 CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients
Non-left Bundle Branch Block · Ischemic or Non-ischemic Cardiomyopathy
Primary: Number of Patients With Improved Clinical Composite Score — 86; 45 Participants — p=0.001
N/A N=43 ACC - Atrial Contribution to CRT
Dilated Cardiomyopathy
Primary: Aortic Velocity Time Integral (VTI) — 22.4; 21.7; 19.4; 18.1 cm
N/A N=302 Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter
Atrial Flutter
Primary: Procedure-related Complication-free Rate — 92.7; 98.2 percentage of subjects
N/A N=240 PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
Left Ventricular Dysfunction
Primary: Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort). — -2.29; -3.43 percentage — p=0.4347
N/A N=20 ECG Belt to Assess Electrical Synchronization
Bradycardia · Heart Failure
Primary: • ECG Belt Analysis of Standard Deviation of Activation Times (SDAT) of LBBP Compared to Native Conduction — 38.6; 20.5 ms
N/A N=77 Micra Atrial TRacking Using A Ventricular AccELerometer 2
Atrioventricular Conduction Block
Primary: Atrial Ventricular Pacing Synchrony Success During Rest — 0; 38; 0; 2 Participants — p=<0.001
N/A N=98 ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction
Bradycardia
Primary: LVEF — 64.22; 63.14; 59.96 % LVEF — p=0.1734
N/A N=157 AVAI: Atrial Ventricular Arrythmia Incidence
Ventricular Tachycardia · Atrial Fibrillation
Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=34 Cryoablation of AF: Improving the Use of the Achieve Catheter
Atrial Fibrillation
Primary: Real-time Documentation of Pulmonary Vein Disconnection — 125 number of PVs disconnected in realtime
Phase 4 N=50 Safety of Argatroban Infusion in Conduction Disturbances
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds
N/A N=12 Atrial Deganglionation as a Therapy for Cardiac Surgery Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: The Number of Patients in Sinus Rhythm at 12 Months. — 12 Participants
Phase 4 N=526 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia. — 64.7; 68.2 Percent of VT…
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 3 N=150 Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System
Typical Atrial Flutter
Primary: Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure — 3 participants
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
Phase 3 N=572 Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia
AtrioVentricular Nodal Reentrant Tachycardia · Supraventricular Tachycardia · Heart Disease
Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001
N/A N=224 Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block
Anesthesia
Primary: Number of Patients With Complete Sensory Block — 91; 79 percentage of participants — p=<0.01
N/A N=20 EGM Analysis in Idiopathic Outflow Tract Ventricular Arrhythmia
Ventricular Outflow Tract Tachycardia
Primary: Percent of Ablation Targets With Termination of the Clinical Ventricular Arrhythmia After RF Energy Delivery — 20 Participants
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants